Advanced Drug Delivery Systems for Colonic Disorders

1st Edition - November 4, 2023
Imprint: Academic Press
Editors: Harish Dureja, Raimar Loebenberg, Sachin Kumar Singh, Muralikrishnan Dhanasekaran, Kamal Dua
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 4 0 4 4 - 0
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 4 0 4 5 - 7

Advanced Drug Delivery Systems for Colonic Disorders presents state-of-the-art methods for targeted drug delivery to the colon. These methods can prolong drug half-lives, improve b… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Advanced Drug Delivery Systems for Colonic Disorders presents state-of-the-art methods for targeted drug delivery to the colon. These methods can prolong drug half-lives, improve bioavailability, optimize pharmacokinetics, and reduce medication dosing frequency. Chapters allow readers to not only become familiar with advancements, but also understand concepts by providing illustrations, figures, and informative tables. Contents cover an overview of colonic diseases, the cellular and molecular mechanisms involved, current and traditional therapeutic approaches, biomaterials, oral drug delivery methods, targeted drug delivery, nutraceuticals and herbal medicine approaches, prebiotics, probiotics and symbiotics, nanomedicine approaches, and the status of clinical trials.

This book is the perfect resources for researchers in pharma, biomaterials, and nutrition to help familiarize them with new and upcoming therapeutic methods. Research physicians in GI can also benefit from reading this book for its clinical applications.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Chapter 1. Introduction to colonic disorders
Abstract
1.1 Introduction
1.2 Classification of colon disorders
1.3 Inflammatory bowel disease
1.4 Diverticulosis
1.5 Colon cancer
1.6 Formulation approaches for targeting colon
1.7 Conclusion
References
Chapter 2. Cellular and molecular mechanisms involved in colonic disorders
Abstract
2.1 Introduction
2.2 Molecular mechanisms involved in colonic disorders
2.3 Conclusion
References
Chapter 3. Current approaches for treatment of colonic disorder
Abstract
3.1 Introduction
3.2 Different type of colonic disorder and their treatment
3.3 Alternative and complementary approaches
3.4 Neurokinin antagonists and Κ-opioid agonists
3.5 Ischemic colitis
3.6 Constipation
3.7 Conclusion and future perspective
References
Chapter 4. Polysaccharides based drug delivery systems for the treatment of colon diseases
Abstract
4.1 Introduction
4.2 Types of polysaccharides
4.3 Tempering in structural arrangement of polysaccharides
4.4 Physicochemical properties of polysaccharides
4.5 Biotolerance properties
4.6 Development of theranostics
4.7 Polysaccharide-based devivery systems
4.8 Analyses of colon-specific carriers in vitro and in vivo
4.9 Conclusion
References
Chapter 5. Synthetic polymers as biomaterials for the treatment of colon diseases
Abstract
5.1 Introduction
5.2 Colon diseases
5.3 Colon delivery: physiology and biopharmaceutical considerations
5.4 Synthetic polymers as biomaterials for colon drug delivery system
5.5 Industrial patents and marketed preparations
5.6 Conclusion
References
Chapter 6. Mucoadhesive polymers as biomaterials for the treatment of colon disorders
Abstract
6.1 Introduction
6.2 Mucoadhesive drug delivery systems
6.3 Mucoadhesive polymers in drug delivery system
6.4 Recent advances in mucoadhesive polymers for colon disorders
6.5 Limitations of mucoadhesive polymers-based drug delivery approaches for the treatment of colon disorders
6.6 Future perspectives
6.7 Conclusion
References
Chapter 7. Colon-responsive oral drug delivery for combating colonic disorders
Abstract
7.1 Introduction
7.2 Fundamentals of encapsulation technologies for oral delivery for colon diseases
7.3 Recent literature in colon-responsive drug delivery
7.4 Conclusion
References
Chapter 8. Colon-responsive targeted drug delivery for treating colonic disorder
Abstract
8.1 Introduction
8.2 Physiology of the gastrointestinal tract
8.3 Physicochemical properties of drugs influencing CDDS
8.4 Different approaches to colon-targeted drug delivery systems
8.5 Challenges and conclusion
References
Chapter 9. Advancement in targeted drug delivery systems in managing colonic disorders
Abstract
9.1 Introduction
9.2 Colon-responsive targeted drug delivery approaches
9.3 Conclusion
References
Chapter 10. Nutraceuticals and phytoceuticals in the treatment of colon disorders
Abstract
10.1 Introduction
10.2 Nutraceuticals as drug delivery systems for colonic disorders
10.3 Plant materials as DDS for colonic disorders
10.4 Therapeutic effectiveness of nutraceuticals
10.5 Conclusions and future prospectives
References
Chapter 11. Role of prebiotics, probiotics, and synbiotics in the management of colonic disorders
Abstract
11.1 Introduction
11.2 Role of prebiotics in the management of colonic disorders
11.3 Role of probiotics in management of colonic disorders
11.4 Role of synbiotics in the management of colonic disorders
11.5 Conclusion and future prospects
References
Chapter 12. Era of biotics in managing colonic disorders
Abstract
12.1 Introduction
12.2 An introduction to pro-, pre-, and synbiotics
12.3 Intestinal integrity
12.4 Bacterial flora in colonic disorders
12.5 Natural sources of probiotics
12.6 Probiotics in Crohn’s disease and ulcerative colitis
12.7 Conclusion
References
Chapter 13. Innovations in liposomal drug delivery: paving the way for personalized cancer therapy
Abstract
13.1 Introduction to liposomal drug delivery systems
13.2 Role of liposomal drug delivery in colonic disorders
13.3 Development of liposomal formulations for specific types of colon cancer
13.4 Improving the efficacy of the drug delivery system
13.5 Evaluation of liposomal drug delivery efficacy in preclinical models
13.6 Optimization of liposome size and surface charge for maximum tumor accumulation
13.7 Analysis of the pharmacokinetics and biodistribution of liposomal drugs in vivo
13.8 Identification of new drugs that are suitable for liposomal delivery to the colon
13.9 Exploration of the impact of liposomal formulation on drug stability and activity
13.10 Gut microbiome effect on liposomal drug delivery
13.11 Evaluation of liposomal drug delivery as a strategy to overcome resistance to chemotherapy
13.12 Advantages of liposome drug carriers for colon cancer treatment
13.13 Conclusions
References
Chapter 14. Nanoparticulate drug delivery systems for colonic disorders
Abstract
14.1 Introduction
14.2 Novel drug delivery systems
14.3 Conclusion
References
Chapter 15. 3D printing-assisted colon-targeted drug delivery systems
Abstract
Abbreviations
15.1 Introduction
15.2 Design considerations in colon-specific drug delivery systems
15.3 Colon-specific drug delivery systems
15.4 Formulation strategies for colon-targeted drug delivery systems
15.5 3D printing
15.6 Colon-specific drug delivery using 3D-printed tablets
15.7 Conclusion and future outlook
References
Chapter 16. Radiopharmaceutical-based approaches for the determination of colon-targeting efficiency
Abstract
16.1 Introduction
16.2 Instrumentation
16.3 Radiopharmaceuticals used in gamma scintigraphy
16.4 Application of gamma scintigraphy in the determination of colon targeting
16.5 Conclusion
References
Chapter 17. Colonic disorder management: challenges and prospects
Abstract
17.1 Introduction
17.2 Hurdles in colon delivery
17.3 Implications of colon in drug delivery
17.4 Challenges in colon disorders
17.5 Clinical studies on colon disorders
17.6 Prospects in colon disorder management
17.7 Conclusion
References
Chapter 18. Clinical trials and regulatory aspects of drug delivery system for colonic disorders
Abstract
18.1 Introduction
18.2 Challenges faced by conventional colon drug delivery systems
18.3 Need of Advanced drug delivery systems for colonic disorders
18.4 Clinical trials related to advanced drug delivery strategies for colonic disorders
18.5 Regulatory aspects of drug delivery system for colonic disorders
18.6 Conclusion
References
Index

Harish Dureja

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Affiliations and expertise

Professor, Department of Pharmaceutical Sciences, Maharshi Dayanand University, India

Raimar Loebenberg

Prof Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University, Germany. He received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996 for his work on drug delivery using nanoparticles. He joined the University of Alberta in 2000, where he is now a Professor in Pharmaceutical Sciences. His research interests are inhalable nanoparticles to treat lung diseases such as lung cancer and tuberculosis. His lab regularly develops and characterises nanoparticles for various inflammatory diseases and cancer. His lab also hosts a unique pencentury device which assists in effectively delivering nanoparticles to the lungs of rodents. He holds a US patent for the delivery of nanoparticles to the lungs. Another major interest area is Biopharmaceutics, and predicting the oral performance of drugs and botanicals.

Prof Löbenberg is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. The Centre specialises in clinical trial material production, and holds a Health Canada site licence and a drug establishment licence. The Centre has controlled substance licences to synthesise psychedelics in a dedicated chemistry lab. The quality control lab has state-of-the-art analytical instruments and other pharmaceutically relevant performance test instruments. Prof Löbenberg is a former president of the Canadian Society for Pharmaceutical Sciences (2014-2015). He is a member and Vice Chair of the United States Pharmacopeia Dietary Supplement Expert Committee, a Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science, and a member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, and of the Health Canada Scientific Advisory Committee on Opiate Abuse.

Affiliations and expertise

Professor, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Canada

Sachin Kumar Singh

Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Quality Assurance at School of Pharmaceutical Sciences, Lovely Professional University, India. He is an honorary professor at Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, University of Technology Sydney, Australia and School of Medical and Life Sciences, Sunway University, 47500 Sunway City, Malaysia. He has 14 years of teaching and research experience. Dr. Singh has completed one DST-SERB funded project on development of SNEDDS of Polypeptide-k for treatment of diabetes mellitus. He has published 500 plus research papers with cumulative impact of 1500 plus, authored 5 books and 25 book chapters. He has 10 granted patents to his credit. He is expert in development of novel drug delivery systems, synbiotics based formulations, analytical and bioanalytical method development and BA-BE studies. He has graduated 17 PhD students and 35 M Pharmacy students and currently graduating 3 masters and 6 PhD students. He is also featured under top 2% scientists of world as per the list of 2021, 2022 and 2023, published by Stanford University, USA. Currently his “h” index is 48 with 11000 plus citations. He is a recipient various national awards including Dr. B.C. Deb memorial award for popularization of science-2020 (honoured by Indian Science Congress Association), Bharat Shiksha Ratan Award-2014 (by Global Society for Health and Educational Growth, Delhi, India) and Bharat Gaurav Puraskar-2022 (by KTK outstanding achievers and education foundation, New Delhi) and Distinguished Alumnus Award (by Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka).

Affiliations and expertise

Professor and head of Pharmaceutical Chemistry and Pharmaceutical Analysis, School of Pharmaceutical Sciences, Lovely Professional University, India

Muralikrishnan Dhanasekaran

Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology.

Affiliations and expertise

Professor of Pharmacology and Toxicology ,Department of Drug Discovery and Development,Harrison College of Pharmacy, Auburn University, Auburn, USA

Kamal Dua

Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the University of Technology Sydney (UTS). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Affiliations and expertise

Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Advanced Drug Delivery Systems for Colonic Disorders

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Harish Dureja

Raimar Loebenberg

Sachin Kumar Singh

Muralikrishnan Dhanasekaran

Kamal Dua

Related books